Suppr超能文献

非酒精性脂肪性肝病:组织学评估系统的利弊

Nonalcoholic Fatty Liver Disease: Pros and Cons of Histologic Systems of Evaluation.

作者信息

Brunt Elizabeth M

机构信息

Department of Pathology and Immunology, Washington University School of Medicine, Campus Box 8118, St. Louis, MO 63110, USA.

出版信息

Int J Mol Sci. 2016 Jan 13;17(1):97. doi: 10.3390/ijms17010097.

Abstract

The diagnostic phenotype of nonalcoholic fatty liver disease (NAFLD)--in particular, the most significant form in terms of prognosis, nonalcoholic steatohepatitis (NASH)--continues to rely on liver tissue evaluation, in spite of remarkable advances in non-invasive algorithms developed from serum-based tests and imaging-based or sonographically-based tests for fibrosis or liver stiffness. The most common tissue evaluation remains percutaneous liver biopsy; considerations given to the needle size and the location of the biopsy have the potential to yield the most representative tissue for evaluation. The pathologist's efforts are directed to not only global diagnosis, but also assessment of severity of injury. Just as in other forms of chronic liver disease, these assessments can be divided into necroinflammatory activity, and fibrosis with parenchymal remodeling, in order to separately analyze potentially reversible (grade) and non-reversible (stage) lesions. These concepts formed the bases for current methods of evaluating the lesions that collectively comprise the phenotypic spectra of NAFLD. Four extant methods have specific applications; there are pros and cons to each, and this forms the basis of the review.

摘要

非酒精性脂肪性肝病(NAFLD)的诊断表型——尤其是就预后而言最重要的形式,非酒精性脂肪性肝炎(NASH)——尽管基于血清检测、基于成像或超声检测纤维化或肝脏硬度的非侵入性算法取得了显著进展,但仍继续依赖肝脏组织评估。最常见的组织评估仍是经皮肝活检;对活检针大小和活检部位的考量有可能获取最具代表性的组织用于评估。病理学家的工作不仅指向整体诊断,还包括损伤严重程度的评估。正如在其他形式的慢性肝病中一样,这些评估可分为坏死性炎症活动以及伴有实质重塑的纤维化,以便分别分析潜在可逆性(分级)和不可逆性(分期)病变。这些概念构成了当前评估共同构成NAFLD表型谱病变方法的基础。现有四种方法有特定应用;每种方法都有优缺点,这构成了本综述的基础。

相似文献

1
Nonalcoholic Fatty Liver Disease: Pros and Cons of Histologic Systems of Evaluation.
Int J Mol Sci. 2016 Jan 13;17(1):97. doi: 10.3390/ijms17010097.
2
Pathology of nonalcoholic steatohepatitis.
Hepatol Res. 2005 Oct;33(2):68-71. doi: 10.1016/j.hepres.2005.09.006. Epub 2005 Oct 7.
3
Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
World J Gastroenterol. 2014 Nov 14;20(42):15539-48. doi: 10.3748/wjg.v20.i42.15539.
5
Nonalcoholic fatty liver disease: one entity, multiple impacts on liver health.
Cell Biol Toxicol. 2017 Feb;33(1):5-14. doi: 10.1007/s10565-016-9361-x. Epub 2016 Sep 28.
6
Histopathological Diagnosis of Nonalcoholic Steatohepatitis (NASH).
Methods Mol Biol. 2022;2455:1-18. doi: 10.1007/978-1-0716-2128-8_1.
8
Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease.
Gastroenterology. 2016 Jun;150(8):1811-1822.e4. doi: 10.1053/j.gastro.2016.03.008. Epub 2016 Mar 19.
9
The Use of Liver Biopsy in Nonalcoholic Fatty Liver Disease: When to Biopsy and in Whom.
Clin Liver Dis. 2018 Feb;22(1):109-119. doi: 10.1016/j.cld.2017.08.006.
10
Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD).
Scand J Gastroenterol. 2020 Jun;55(6):706-711. doi: 10.1080/00365521.2020.1766554. Epub 2020 Jun 1.

引用本文的文献

2
Effect of resveratrol on key signaling pathways including SIRT1/AMPK/Smad3/TGF-β and miRNA-141 related to NAFLD in an animal model.
Res Pharm Sci. 2025 Jun 17;20(3):434-444. doi: 10.4103/RPS.RPS_220_24. eCollection 2025 Jun.
5
Digital pathology for nonalcoholic steatohepatitis assessment.
Nat Rev Gastroenterol Hepatol. 2024 Jan;21(1):57-69. doi: 10.1038/s41575-023-00843-7. Epub 2023 Oct 3.
7
Histological assessment based on liver biopsy: the value and challenges in NASH drug development.
Acta Pharmacol Sin. 2022 May;43(5):1200-1209. doi: 10.1038/s41401-022-00874-x. Epub 2022 Feb 14.
8
Liver stiffness measurement by magnetic resonance elastography is not affected by hepatic steatosis.
Eur Radiol. 2022 Feb;32(2):950-958. doi: 10.1007/s00330-021-08225-w. Epub 2021 Aug 25.
9
Moderately Macrosteatotic Livers Have Acceptable Long-Term Outcomes but Higher Risk of Immediate Mortality.
Transplant Proc. 2021 Jun;53(5):1682-1689. doi: 10.1016/j.transproceed.2021.03.024. Epub 2021 Apr 27.
10
Removal of Epididymal Visceral Adipose Tissue Prevents Obesity-Induced Multi-organ Insulin Resistance in Male Mice.
J Endocr Soc. 2021 Feb 20;5(5):bvab024. doi: 10.1210/jendso/bvab024. eCollection 2021 May 1.

本文引用的文献

1
Nonalcoholic fatty liver disease.
Nat Rev Dis Primers. 2015 Dec 17;1:15080. doi: 10.1038/nrdp.2015.80.
4
A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver.
J Hepatol. 2013 Sep;59(3):550-6. doi: 10.1016/j.jhep.2013.04.027. Epub 2013 May 9.
5
Development and validation of a new histological score for pediatric non-alcoholic fatty liver disease.
J Hepatol. 2012 Dec;57(6):1312-8. doi: 10.1016/j.jhep.2012.07.027. Epub 2012 Aug 4.
7
Features, diagnosis, and treatment of nonalcoholic fatty liver disease.
Clin Gastroenterol Hepatol. 2012 Aug;10(8):837-58. doi: 10.1016/j.cgh.2012.03.011. Epub 2012 Mar 23.
8
Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research.
Semin Liver Dis. 2012 Feb;32(1):3-13. doi: 10.1055/s-0032-1306421. Epub 2012 Mar 13.
10
Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease.
J Hepatol. 2011 Sep;55(3):654-659. doi: 10.1016/j.jhep.2010.11.021. Epub 2010 Dec 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验